The Comparison of XELOX and EOX in the First-line Treatment of Advanced Gastric Cancer

• Status: Completed
• Trial end date: 2021-02-23
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to compare the efficacy and safety of XELOX regimen with EOX regimen in the first-line treatment of advanced gastric cancer patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Fudan University
• Treatments: Capecitabine; Epirubicin; Oxaliplatin

Criteria

Major inclusion criteria

• had a histologically proven adenocarcinoma of the gastroesophageal junction, or stomach that was locally advanced (inoperable) or metastatic

• measurable disease, according to the Response Evaluation Criteria in Solid Tumors (RECIST)1.1

• an Eastern Cooperative Oncology Group performance status of 0 to 2

• adequate renal, hepatic, and hematologic function

Major exclusion criteria

• previous chemotherapy or radiotherapy (unless in the adjuvant setting)

• uncontrolled cardiac disease, or other clinically significant, uncontrolled coexisting illness or previous or concurrent cancer

• accumulated dose of Epirubicin exceeds 300mg/m2

• HER2 positive and willing to use trastuzumab